Bd launches state-of-the-art cloud software solution to streamline flow cytometry research

New  bd® research cloud provides scientists with an integrated ecosystem that allows for optimizing panel design, collaboration and analysis franklin lakes, n.j. , sept. 27, 2022 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today launched bd® research cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher quality experiments with faster time to insight for scientists working across a range of disciplines including immunology, virology, oncology and infectious disease monitoring.
BDX Ratings Summary
BDX Quant Ranking